PORTFOLIO Blue Earth Blue Earth Diagnostics was founded to develop and commercialise molecular imaging agents, addressing areas of high unmet medical need. The company’s first approved and commercially available product, Axumin®, is clinically proven to target and image prostate cancer cells. Axumin was reviewed by the US Food and Drug Administration and was granted US regulatory approval in Q2 2016. Marketing authorisation in Europe was granted by the European Medicines Agency in Q2 2017. Building a profitable company delivering transformational impacts for patients Sold to Bracco Imaging in 2019 for $476m £337m million of proceeds 87% IRR 9.9x multiple of cost Blue Earth was established by Syncona in 2014 when Axumin, a PET imaging agent, then in clinical development, was licensed from GE Healthcare Set-up with the ambition of building a world-leading prostate cancer imaging company, developing molecular imaging technologies to reliably inform diagnosis and treatment decisions In just two years, the company received regulatory approval in the US for Axumin in prostate cancer and the it went onto to achieve pricing reimbursement and a successful commercial launch It has had a transformational impact for patients in an area of high unmet medical need: In the company’s FALCON trial, 61% of patients undergoing an Axumin scan have had a ‘change in management’ in the way their disease is treated 28,000 patients have been treated since the company’s launch The company is profitable and has seen continued strong financial performance Other previous investments portfolio companies Other domain areas Cell therapy Gene therapy Biologics Small molecule Sign-up for company news alerts Get the latest RNS, company news, share price information and results from Syncona RNS ALERTS COMPANY ALERTS Contact Syncona Investment Management Limited 2nd Floor 8 Bloomsbury Street London WC1B 3SR contact@synconaltd.com Explore About us Our people Portfolio Sustainability News and Insights Investors Contact Copyright © Syncona 2021 Accessibility Privacy & cookies Employee privacy notice Third party privacy notice Regulatory publications Modern Slavery Statement Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD. Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited. Designed & built by SampsonMay Accept to continue or find out more in our cookie policy. Change settings ACCEPT AND CLOSE